NOTE: This activity is available only as part of a paid subscription series; it is not available for purchase as a single, stand-alone activity. The goal of this program is to improve management of patients with cancer with chimeric antigen receptor (CAR) T cell therapy. After hearing and assimilating this program, the clinician will be better able to: 1. Anticipate neurotoxicity and cytokine release syndrome after treatment with CAR T cell therapies. 2. Choose B cell maturation antigen-targeted therapies for treatment of multiple myeloma. 3. Identify patients with lymphoma for whom autologous stem cell transplantation is the preferred treatment. 4. Differentiate B cell maturation antigen-targeted therapies from CD19 CAR T cell therapies. 5. Select a lymphodepletion regimen for patients with relapsed or refractory Hodgkin lymphoma.
- Provider:Lippincott Continuing Medical Education Institute, Inc.
- Activity Link: https://www.audio-digest.org/Specialties/Oncology
- Start Date: 2024-01-17 06:00:00
- End Date: 2024-01-17 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.75 hours
- MOC Credit Details: ABIM - 1.75 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Medical Oncology